

Research

Open Access

Expression of yeast deubiquitination enzyme **UBP1** analogues in *E. coli*

Anna Wojtowicz*, Anna Mazurkiewicz-Pisarek, Grazyna Plucienniczak, Diana Mikiewicz-Sygula, Luiza Chojnacka, Natalia Lukasiewicz and Andrzej Plucienniczak

Address: Institute of Biotechnology and Antibiotics, Staroscinska 5,02-516 Warsaw, Poland

Email: Anna Wojtowicz* - wojtowicza@iba.waw.pl; Anna Mazurkiewicz-Pisarek - mazurkiewicza@iba.waw.pl;

Grazyna Plucienniczak - plucienniczak@iba.waw.pl; Diana Mikiewicz-Sygula - mikiewicz@iba.waw.pl;

Luiza Chojnacka - chojnacka@iba.waw.pl; Natalia Lukasiewicz - Lukasiewicz@iba.waw.pl; Andrzej Plucienniczak - apl@iba.waw.pl

* Corresponding author

Published: 30 May 2005

Received: 18 May 2005

Microbial Cell Factories 2005, 4:17 doi:10.1186/1475-2859-4-17

Accepted: 30 May 2005

This article is available from: <http://www.microbialcellfactories.com/content/4/1/17>

© 2005 Wojtowicz et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: It has been shown that proteins fused to ubiquitin undergo greater expression in *E. coli* and are easier to purify and renature than nonhybrid foreign proteins. However, there is no commercial source of large quantities of specific deubiquitinating proteases. This is the reason why hybrid proteins containing ubiquitin at their N-end cannot be used in large scale biotechnological processes.

Results and Conclusion: We have described the synthesis of the yeast deubiquitination enzyme UBPI muteins in *E. coli*. We have shown that an efficient overproduction of the enzyme in *E. coli* may be achieved after the introduction of several changes in the nucleotide sequence encoding UBPI. One of the conditions of an effective synthesis of the UBPI muteins is the removal of the 5'-end sequence encoding the transmembrane region of the enzyme. The obtained variants of the enzyme may be successfully used for processing large amounts of hybrid proteins comprising ubiquitin or tagged ubiquitin at their N-ends.

Background

Ubiquitin is composed of 76 amino-acid residues with a total molecular mass of 8.6 kDa. This protein is an element of the universal protein modification in eukaryotes called ubiquitination, a phenomenon which does not occur in bacteria. In spite of that, it has been shown that proteins fused to ubiquitin undergo greater expression in *E. coli* and are easier to purify and renature than nonhybrid foreign proteins [1]. However, to take advantage of these properties of hybrid proteins in technological processes, large amounts of proteases for cleaving specifically

ubiquitin from those proteins are necessary. Protease UBPI, an enzyme found in the yeast *Saccharomyces cerevisiae*, is a candidate for becoming such a tool. The enzyme was described in 1991 [2] and is the subject of a patent application [3]. UBPI is a cysteine protease which cleaves ubiquitin from protein fused to its C-end. Its activity and culture conditions in *E. coli* have been described [2], but the problem of a larger and more efficient production of the enzyme remains unsolved and for that reason technical applications of the inventions mentioned in [3] have not been possible.

The aim of this work was to obtain an expression system for an efficient synthesis of UBP1 protease variants that would be useful in industrial processes.

Results and Discussion

We were not able to obtain an efficient expression of the full coding sequence of *UBP1*. This is in agreement with the results of Tobias and Varshavsky [2], who were able to detect UBP1 in *E. coli* only after an immunoblot analysis. A possible reason for this situation might be the presence of a transmembrane region in the N-end part of the protein, which was discovered after a computer analysis using the TMHMM v. 2.0 software package (CBS, Denmark) [4]. The region encompasses amino-acids 34–51 (Figure 1). Because of that, we decided to prepare truncated variants of the sequences encoding *UBP1* without the transmembrane region. Using the PCR technique, two shortened genes were prepared without the 5' parts of the *UBP1* coding region. Proteins encoded by these variants of the gene are shorter by 54 and 98 amino-acids (Figure 1). Expression of these analogues of the *UBP1* gene inserted into pT7RS derivatives was analyzed. In addition, the influence of one mutation, named Q754L, within the *UBP1* gene, which happened during PCR amplification, on the expression level was investigated (Figure 1A).

Expression of the *UBP1* variants in *E. coli*

The obtained plasmids with the hybrid genes encoding the analogues: *UBI::UBPD*, *UBI::UBPDQL*, and *UBI::UBPD2QL* were used to transform the *E. coli* BLD21 strain. In general, several expression host strains and different culture conditions were examined (results not shown) in our mini-induction screening experiments to optimize recombinant protein expression. The cultures were grown at 37°C and 25°C until $OD_{600\text{ nm}}$ reached 0.5–1.8 and 1 ml samples were removed from each culture and saved as controls. Then, isopropyl β -D-thiogalactoside was added to the cultures at the desired concentration of 0.5–1.0 mM. Aliquots of cultures were taken 30, 60, 90, 120 and 150 min. post-induction (Figure 2). Cell density in these samples was measured to monitor the protein induction process and to normalize total proteins in *E. coli* after cell lysis in the 2xSDS sample buffer. The expression level (Figure 3) of the recombinant proteins was determined by a densitometric analysis of the electrophoretic pattern. The protein level was equal to 7.2 % and 9.8 % of the proteins visible in lines 2 and 5 (Figure 3) for *UBPDQL* and *UBPD2QL*, respectively. The results shown in Fig. 4 and 5 indicate that the fusions of ubiquitin with *UBP1* analogues are active proteases during cell culture because an intensive band of ubiquitin is visible on SDS gels after electrophoresis of *E. coli* lysates.

The main factors influencing the expression level of *UBP1* analogues and growth rate of bacteria are: the presence or

absence of the Q754L mutation (Figure 5) and lack of the transmembrane region at the N-end of *UBP1* (Figure 3). The lack of Q754L mutation in the *UBP1* analogue gene makes an efficient production of the enzyme impossible because of a very slow culture growth rate and a low level of protease expression (results not shown). Apart from that we have shown that the removal of the transmembrane region leads to a significant reduction in growth time and an increase in the expression level (Figure 3). The period of time to reach $OD_{600} = 1$ for *UBPD*, *UBPDQL* and *UBPD2QL* was 48, 12 and 9 h, respectively. It appears also that the bacteria containing the vector with the shorter gene of the *UBP1* analogue encoding *UBPD2QL* produce the highest amount of the recombinant protease (Figure 3 and 4). It was also established that the presence of the proper codons in the gene used for expression additionally shortened the period of time necessary to reach $OD_{600} = 1$ (results not shown). All things considered, the best expression system consists of the gene variant with the Q754L mutation, larger deletion of the N-end encoding sequence and proper codon usage. The best results were obtained when the bacteria culture was carried out at 25°C, the induction with IPTG begun when OD had reached 1 and when the culture time after induction was 2h (Figure 2).

Purification of the recombinant *UBPD2QLHisx6* protease and fusion proteins of the type *6xHisUBI::protein*

For purification, the cells from 0.5 litre culture after a 2-hour induction at 25°C in the presence of 1 mM IPTG were harvested. The pellet was resuspended in 50 ml of buffer A. All subsequent steps were performed at 4°C. The cells were disrupted by sonication on ice and the insoluble debris was removed by centrifugation for 25 min. at 11500 rpm. The cleared extract was chromatographed on a Ni-NTA Superflow column, pre-equilibrated with 10 vol. of buffer A. After loading, the column was washed with 5 vol. of buffer B and then the protease was eluted twice with elution buffer C. Protein concentrations were determined using the Bradford dye binding assay and bovine serum albumin as the standard. Both analogues of *UBP1*, *UBPDQL* and *UBPD2QL*, were purified in the same manner. Digestion of the two substrates, *6xHisUBI::S* and *UBI::K*, shows that the preparations of the two different *UBP1* analogues are active proteases, but the activity of the shorter one (*UBP1DC2*) is higher (Figure 6). Stability of both the *UBPDQL* and *UBPD2QL* analogues during long exposure to 37°C was also investigated. It appeared that both enzymes were active after 24 h incubation (results not shown).

We obtained 13.8 mg of purified *UBPDQL* and 20 mg of purified *UBPD2QL* from 1 l of *E. coli* culture. The amounts represent 6.3% and 7.4% of the total protein obtained after the destruction of bacterial cells, and

A

```

M D L F I E S K I N S L L Q F L F G S R Q D F L R N F K T 29
1 ATGGATTGTTTATTGAAGCAAGATAAACGATTTATTACAATTTTATTTGGTCCCGACAGGATTTTGGAGAAATTTAAACT
W S N N N N N N L S I Y L L I F G I V V F F Y K K P D H L N 58
88 TCGAGTAAACAACAATCAATCTCATGATTTATTATTAATTTTGGCATAGTAGTATTTTATAAAAAACAGCCATCTAACC
Y I V E S V S E M T T N F R N N N S L S R W L P R S R F T 87
175 TACATTTTGTAGCGCTTAGTGAAATGACAACTTCAGAAATATATAGCCTAGCCGTGCTGCGAAGAGTAGTTTACC
H L D E S I L K R G C F I A G L V W D G N T C F M N S V L 116
262 CACTTAGACGAGAGATCTTGAABAGAGGTGGTTCATTGCTGTTAGTAAATGATGTAACCTGTTTATGAACCTCTGTTTG
Q S L A S S R E L M E F L D N N V I R T Y E E I E Q N E H 145
349 CATTTCATGGATCATCCAGAGATTAATGAGTCTTGGACATAATGTCATAAGGACCTATGAGGAGATAGAACAATGAACAC
N E E G F S G E S A Q D E A T H K K N T R K G G K V Y G K 174
436 AATGAAGAAAGAAACGGCAAGATCTGCTCAGATGAGCCACTCTAAGAAAACACTGTAAGCGGTGGCAAGTTTATGATGAG
H K K K L N R K S S S K E D E E K S Q E P D I T F S V A L 203
523 CATAGAAGAATTAATGAGGAGTCAAGTTCGAAAGAACGAAAGAACGAGCCAGGACCATATCACTTTCAGTTCGCGCTTA
R D L L S A L N A K Y Y R D K P Y F K T N S L L K A M S K 232
610 AGGATCTACTTTCGCTTAATGCGAAGTATATCGGATAACCCCTATTCAAACCAATGTTTATGAAGCAATGTCACAA
S P R K N I L L G Y D Q E D A Q E F P Q N I E A E L E S N 261
697 TCTCAAGAAAAATATCTTTCGCTACGACCAAGAGGACCGCAAGAATCTCCAGAACATACAGCCGATGGAAAGTAC
V K S L N T E K L D T T P V A K S E L P D D A L V G Q L N 290
784 GTTAAATCATTGAATACTGAAAACTAGATACCACTCCAGTTCGGAATCAGAATACCCGATGATGCTTAGTAGTCAACTTAC
L G E V G T V Y I P T E Q I D P N S I L H D K S I Q N F T 319
871 CTTGCGAAGTGGCACTGTTTACATCCAGTCGACAGATGATCCCTACCTATACACAGACAGCCATCAAAATTTGACA
P F K L M T P L D G I T A E B I G C L O C G E N G G I R Y 348
958 CTTTCAAACATAGTACTCTTATAGATGGTATCACCGCAGAAAGATTGGTGTTCAGAGTGGGTGAGAACGGGATAGATAT
S V F S G L S L N L P N E N I G S T L K L S Q L L S D W S 377
1045 TCCGATTTTCGGGATAGCGTAAATTTACCGAAGAGAAATATGGTTCACCTTAAATATCTCAGTATTAAGCCACTGGAGT
F P E I I E G V E C N R C A L T A A E S H L E G Q L K E F 406
1132 AAACCTGAATCATCGAAGCGGTAGAAATGTAACCGTCTCCCTCACAGAGCCACTCTCAATTTATGTCAGTCAAGAATTT
E K K P E G S I P E K P I N A V K D E V H Q I E E V L A K 435
1219 GAAAAAACCCTGAGGTTGATTCOCGAAAAGCCAAATAACCGCTGAAAAGATAGGGTCCATCAATCGAAGAAGTTTTCGCAAA
P V I D D E D Y K K L H T A N M V R K C S K S K O I L I S 464
1306 CCGATTTTGCAGATGAAGATTAAGAAGTTCATACAGAAATATGGTACGTAATGCTTAATCTAAGCAGATTTTAAATACA
R P P P L L S I H I N E S V F D P R T Y M I E K N N S K V 493
1393 AGACCTCCACCATATATCCATCATATCAACAGATCCCGTATTTGATCCAGAACGTAATGATAGAAAAAATACTCGAAGTA
L F K S R L N L A P W C C D I N E I N L D A R L P M S K K 522
1480 TTGTTTAAGTCAAGTTGAATCTTCCCATGGTGTGTGATTAATGAATCAATTTGGAAGCTGCTTTCGCAATGCAAAAAG
E K A A Q Q D S S E D E N I G G E Y Y T K L H E R F E Q E 551
1567 GAAAAGCTGGCAACAGATTCAGTGAAGTGAACAATTTGGCGTGAATACTATACGAATTACATGAACGCTTCGAGCAGAA
F E D S E E E E Y D D A E G N V A S H Y N H T K D I S N 580
1654 TTTGAAGACGCGAGGAGAAAAAATACGATGACCGAGGGGAACATGCGCTCATACAAATACCAAGGATATCACTAAC
Y D P L N G E V D G V T S D D E D E Y I E E T D A L G N T 609
1741 TATGATCCCTAAACGGTGAAGTGCATGGCGTACATCCGATGATGAAGATGAGTACATTGAAGAAACCGATGCTTAGGAAATACA
I R K R I I E H S D V E N E N V R D N E E L Q R I D N V S 638
1828 ATCAAAAGAGCATAGACATCTGATCTGAAACGAGAAATGTAAGAAATGATGACACTCCAGAAATCCACATGTCAGC
L D E P K I N V E D Q L E T S S D E E D V I P A P P I N Y 667
1915 CTTGACGAACCAAGATCAATGTTGAAGATCACTAGAACATCATCTGATGAGGAAGATGTTATACAGCTCCACCTATCAATAT
A R S F S T V P A T P L T Y S L R S V I V H Y G T H N Y G 696
2002 GCTTAGTCAATTTCCAGTTCAGCCACTCATTGACATATTCATGGCGCTGTCATGTTTACTACGGTACCCATTAATATGTT
H Y I A F K Y B G C W R I S D E T V Y V D E A E V L 725
2089 CATTACATTCATTTAGAAATACAGGGTGTGGTGGAGATATCTGATGACTGTTGATGCTGTTGGGACGAGCTGAATCTCT
S T P G V F M L F Y E Y D F D E E T G K M K D D L E A I Q 754
2176 TCAACCCCGGTGATTTATTTTACGAATATGACTTTGATGAAGAACTGGGAAGATGAAGGATTTGGAGCTATTAG
S N N E D D E K E Q E Q K G V Q E P K E S Q E Q G E G E 783
2263 AGTAAATGAGAGATGATGAAAAGCAGGAGCAAAAAGAGTCCAGAGCCAAAGGAAGCCAGAGCAAGGAGAGGTGAA
E Q E E C Q E Q M K F E R T E D H B D I S G K D V N 809
2350 GACCAGAGGAGGCTCAGAGCAGATGAAGTTCGAGAGAACAGAACCATAGAGATTTCTGGTAAAGATGTAACATA
    
```

B




Figure 1

Nucleotide and amino-acid sequences of the yeast *UBP1* gene and *UBP1* protease [2]. A) The nucleotide residues are numbered on the left, and amino acid residues are numbered on the right of the figure. The underlined AGA or AGG arginine and TTA leucine codons were changed for CGC or CGT and CTG and CTG triplets, respectively. The CAG triplet (shown in bold) at positions 2260–2262 was changed to CTG one (Q754L mutation). The amino-acids forming active centre is shown in italics [4]. For the construction of *UBI::UBPDQL* or *UBI::UBPD2QL* coding sequences the first 162 bp or 294 bp which were removed are overlined or underlined, respectively. The 3'part of the *UBP1* gene (positions: 2074–2430) was used to construct the S protein, the truncated hybrid protein which was used to determine the *UBP1* variants' activity. B) Schematic structure of *UBI::UBP1* construction variants. ▨ – ubiquitin, □ – *UBP1*, ▩ – 6xHis.




Figure 2

Dependence of the expression level of the shorter analogue of UBPI, UBPD2QL, on the time after IPTG induction as revealed by SDS electrophoresis in 12% polyacrylamide gel. *E. coli* BL21 (DE3) cells transformed by the plasmid pT7UPD2QL were cultured at 25°C in LB, and induced by the addition of IPTG to the final concentration of 1 mM. Aliquots of cultures were taken at: 1 – 0 min, 2 – 30 min, 3 – 60 min, 4 – 90 min, 5 – 120 min, 6 – 150 min after induction.

correspond to 710 U of the purified UBPDQL and 1650 U of UBPD2QL, respectively.

We would like to stress that the presence of 6xHis at the C-end of UBPI analogues may greatly facilitate purification of the recombinant protein containing ubiquitin tagged at its N-end with 6 histidine residues. We propose a three steps procedure: 1) purification of the fusion protein on a Ni-NTA column followed by dialysis; 2) digestion of the purified fusion with a UBPI analogue, and 3) chromatography of the digestion mixture on the same column. The protein 6xHisUBI::S, used for activity determination, was treated in this way (Figure 7). SDS-PAGE image analysis showed that this simple procedure leads to an almost pure peptide because of the undigested fusion protein. His-tagged ubiquitin and protease bind to the Ni-NTA column while after the digestion of the fusion, the liberated protein flows out of the Ni-NTA column. Such an approach

greatly simplifies the purification of the fusion proteins and the limited number of purification stages greatly enhances the efficiency of the whole process.

It should be noted that a solution similar to ours, produced artificially as a result of UBPI gene truncation [6], was observed by Schmitz et al. [7], who discovered two forms of UBPI in the yeast cells, the anchored and the soluble one.

Conclusion

Our results show that an efficient expression of the unmodified yeast *UBP1* protease gene in *E. coli* in the presented expression system is impossible. The most important change to be introduced into the *UBP1* gene is the Q754L mutation leading to the replacement of glutamine by leucine at position 754 in the aa sequence in the yeast UBPI. The removal of the transmembrane N-end region




Figure 3

Expression level of the *UBP1* analogues as revealed by SDS electrophoresis in 12% polyacrylamide gel. 1 and 2 – lysates of *E. coli* BLD3(DE3) bacteria transformed with pT7UPD2QL, not induced and induced with IPTG from cultures maintained in 100 ml LB media, respectively; 3 – supernatant after sonication of the bacteria culture performed in the fermenter; 4 and 5 – lysates of *E. coli* BLD3 bacteria transformed with pT7UPDQL, cultured, not induced and induced with IPTG, respectively.

of *UBP1* improves the level of expression of a properly truncated gene. Both of these changes in the gene decrease the time needed for bacteria cultivation.

We have shown that using protease analogues, tagged at the C-end by 6xHis, for cleaving fusion proteins containing N-end His-tagged ubiquitin of the type 6xHisUBI::protein facilitates purification of the protein present in the hybrid to a great extent.

The high expression level in *E. coli* of our *UBP1* analogues allows the use of ubiquitin::protein fusion in large scale production of recombinant proteins.

Methods

Bacterial Strains, Plasmids, Enzymes, and Reagents

Saccharomyces cerevisiae, strain W303, was used as a source of the DNA for PCR amplification. The *E. coli* DH5 α , NM522 strains were used for transformations to obtain




Figure 4
Activity of UBPD2QL protease in bacterial cells, SDS electrophoresis in 12% polyacrylamide of bacterial lysates. 1 – molecular mass marker (kDa); 2 and 3 – lysates of *E. coli* BLD3 (DE3) bacteria transformed with pT7UPDQL2, cultured, induced and not induced with IPTG, respectively. The ubiquitin band is marked with an arrow.




Figure 5
Expression level of UBPI analogue with Q754L mutation (UBPQL) as revealed by SDS electrophoresis in 12% polyacrylamide gel. 1 – molecular mass marker (kDa); 2 and 3 – lysates *E. coli* BLD21 (DE3) bacteria transformed with pT7UPQL, cultured, not induced and induced with IPTG, respectively. The UBPQL protease and ubiquitin bands are marked with arrows.




Figure 6

Activity of the UBPI analogues, UBPDQL and UBPD2QL, as revealed by SDS electrophoresis in 12% polyacrylamide gel. 1 and 2 – the substrate 6xHisUBI::S digested with UBPDQL and UBPD2QL, respectively; 3 – the undigested substrate, 6xHisUBI::S; 4 – molecular mass marker (kDa); 5 and 6 – the substrate UBI::K digested with UBPD2QL and UBPDQL; 7 – the undigested substrate, UBI::K.

recombinant plasmids. The *E. coli* BLD21 (DE3) strain was applied to achieve expression of the His6-tagged analogues of the UBPI protease. The plasmid pT7RS (GenBank Accession No. AY923866), containing ArgU tRNA (UCU) gene and the transcription terminator of phage T7 RNA polymerase, was used for the construction of the expression system. The *E. coli* BLD21 (DE3) cells with the pT7RS plasmid derivatives were cultured aerobically at 25°C or 37°C in LB medium supplemented with 50 µg/ml ampicillin. Restriction, modification enzymes were purchased from Amersham Pharmacia Biotech. The reagents for PCR and Ni-NTA Superflow columns were obtained from Qiagen. IPTG, agarose, polyacrylamide and the reagents for protein purification were purchased from Sigma-Aldrich Chemie GmbH, Steinheim, Germany. For site-directed mutagenesis the Stratagene kit was used (Cat. No. 200518-5). We used the GelScan v. 1.45 software package for the densitometric analysis of the electrophoretic image.

The buffers used for the purification of UBPI analogues were: buffer A (50 mM buffer phos. pH 8.0; 0.3 M NaCl; 10 mM imidazol; 10 mM 2-β-mercapthoethanol; 10% glicerol; 0,1% Triton), buffer B (50 mM phosphate buffer, pH 8.0; 0.3 M NaCl; 40 mM imidazol; 10 mM 2-β-mercapthoethanol; 10% glicerol; 0,1% Triton) and buffer C (50 mM phosphate buffer pH 8.0; 0,3 M NaCl; 300 mM imidazol; 10 mM 2-β-mercapthoethanol; 10% glicerol; 0,1% Triton).

Plasmid construction

To facilitate subsequent purification of the UBPI variants or fusion proteins, the pT7CH, pT7NH, pT7U and pT7NHU plasmids were constructed. The first one contains in the 3' polilinker part the 6 histidines coding sequences followed by a TAA stop triplet. The second one was constructed for the addition of 6 histidines tags to the N-ends of hybrid proteins. It contains 6 histidines coding sequences following an ATG triplet.




Figure 7
Digestion of the 6xHisUBI::S fusion with UBPD2QL and purification of peptide S on an Ni-NTA column. SDS electrophoresis in 12% polyacrylamide gel. 1 – molecular mass marker (kDa), 2 – 6HisUbi::S purified in a chromatography column containing Ni-NTA medium, 3 – 6xHisUBI::S digested with protease UBPD2QL, 4 – S protein purified in a chromatography column filled with Ni-NTA medium.

The pT7CH was obtained by inserting a short double stranded DNA fragment formed by two synthetic oligonucleotides, HIST7G and HIST7D (Table 1), into the pT7RS

plasmid digested with *EcoRI* and *HindIII* restriction nucleases. Similarly, the pT7NH was constructed by inserting a

Table 1: Primers for the construction of pT7RS and UBPI derivatives

Primers ^a	Sequences ^b	Restriction site
HIST7G	5' <u>AATTC</u> GATATCGTCGACGGATCC CATCATCACCATCACC ATTAAAAT 3'	EcoRI
HIST7D	5' AGCTATTTTAAATGGTGATGGTGATGATGGGATCCGTCGACGATATCG 3'	BamHI, Sall, EcoRV,
6HisG	5' <u>TATGGCA</u> CATCATCACCATCACC ACTCTGGTTCTG 3'	NdeI
6HisD	5' <u>AATTC</u> GAGAACCAGAGTGGTGATGGTGATGATGTGCCA 3'	EcoRI
UB1G	5' GGGGAATTCATATGCAGATTTTCGTCAAACCTTTG 3'	EcoRI and NdeI
UBID2	5' GGGGATCCCTTAATGCTCTTCACCACCGCGGAGTCTTAAG 3'	BamHI and SacII
UBP1G	5' AGACTCCGCGGTGGTGATTTGTTTATTGAAAGCAAGATA 3'	SacII
UBPID	5' GGGGATCCCTTAGTTTACATCTTTACCAGAAATA 3'	BamHI
UBP1MG	5'GGCATAGTAGTATTTTTTTA CCGCGG TGGTGACCATCTAAACTACATTGT 3'	SacII
UBP1MD	5'ACAATGTAGTTTAGATGGTCACCACCGCGGTAAAAAATACTACTATGCC 3'	SacII
SkrutG	5'AAAACCGCGGTGGTTTCATTGCTGGTTTA 3'	SacII
SkrutD	5'GGAAGAAATTCCTTGC GCGTCCTC 3'	EcoRI
UBP1GC	5'-GATTTGGAAGCTATT CAG AGTAATAATGAAG-3'	
UBP1DC	5'-CTTCATTATTACTCTGAATAGCTTCCAAATC-3'	
KalaG	5'-GATCCAGGCGATAAAGACGGTGATGGCTATATTTCTGCTGCTGAAGCTATGGCTTA-3'	BamHI
KalaD	5'-AGCTTAAGCCATAGCTTCAGCAGCAGAAATATAGCCATCACCGTCTTTATCGCCTG-3'	HindIII

^a The names of primers contain the letters: G – sense or D – antisense.

^b The restriction sites are underlined or overlined. The histidine and leucine codons are in bold face.

Table 2: Plasmids and genes used to construct vectors of the pT7RS derivatives

Vectors	Gene cloned	Result ing vectors	Expression products	Name of the protein used in the text
pT7SR	Ubiquitin	pT7U	Ubiquitin	UBI
pT7U	K	pT7UK	UBI::K	UBI::K
	UBP1	pT7UP	UBI::UBP1	UBP1
pT7CH	UBI::UBP1 with Q754L mutation	pT7UPQL	UBI::UBPQL::6xHis	UBPQL
	UBI::UBP1(55-809) without Q754L mutation	pT7UPD	UBI::UBPD::6xHis	UBPD
	UBI::UBP1(55-809) with Q754L mutation	pT7UPDQL	UBI::UBPDQL::6xHis	UBPDQL
pT7CH	UBI::UBP1(99-809) with Q754L mutation	pT7UPD2QL	UBI::UBPD2QL::6xHis	UBPD2QL
pT7NH	Ubiquitin	pT7NHU	6xHis::UBI	6xHisUBI
pT7NHU	S	pT7NHUS	6xHis::UBI::S	6xHisUBI::S

double stranded DNA fragment formed by 6HisG and 6HisD oligonucleotides (Table 1) into pT7RS digested with NdeI and EcoRI.

The pT7U plasmid contains a nucleotide sequence encoding modified yeast ubiquitin with the SacII restriction nuclease recognition sequence near the 3' end of the sequence, facilitating construction of different hybrid genes. Primers UB1G and UBID2 (Table 1) were used to amplify and modify the ubiquitin gene. The plasmid was used to express the fusion proteins: ubiquitin::modified UBPI.

The pT7NHU plasmid contains a synthetic nucleotide sequence encoding ubiquitin with the codons used most frequently in the *E. coli* genome, inserted into the pT7NH plasmid. This plasmid was used to express a hybrid gene

for the synthesis of the substrate for the determination of UBPI activity.

The UBPI protease gene was obtained using PCR. For amplification, the UBPIG and UBPID primers were used (Table 1). The oligonucleotides contained recognition sites for the restriction endonucleases SacII and BamHI, respectively. The PCR was performed in a 50 µl reaction volume with a buffer containing 50 mM KCl, 1.75 mM MgCl₂, 0.02 mM of each dNTP, 10 mM Tris-HCl (pH 8.9), 100 pM of each primer, the enzyme mixture of Taq and Pwo DNA polymerases (Expand Long Template PCR System, Roche) and 100 ng of total DNA of *S. cerevisiae* as a template for 30 cycles using Eppendorf 5330 thermocycler. Each cycle consisted of 15 sec at 94°C, 15 sec at 56°C, and 2 min at 72°C. The amplified 2430-bp-long DNA fragment was isolated by 1% agarose gel electro-

phoresis using Gel-Out kit (Kucharczyk T. E. Co, Warsaw), digested with *Bam*HI and *Sac*II restriction nucleases, purified and ligated to *Bam*HI and *Sac*II digested pT7U vector. Ligation products were transformed into the NM522 *E. coli* strain. Plasmid DNA was isolated using the alkaline method [8]. Next, the 2430 bp *UBP1* gene was excised from the recombinant plasmid using the restriction enzymes *Nde*I and *Bam*HI, and the DNA fragment encoding hybrid gene *ubiquitin::UBP1* was recloned into the pT7CH plasmid at the *Nde*I and *Bam*HI sites. In this way the pT7UPQL vector was obtained (Table 2).

UBP1 variants

PCR was used to remove the transmembrane domain from the *UBP1* gene. Two variants were obtained. In the first variant, a 162 bp fragment was removed from the 5' part of the coding sequence. For this purpose, site-directed mutagenesis was used with the primers UBPI1MG and UBPI1MD (Table 1). The shortened gene was modified by the addition of '5-GGTGGT-3', the sequence encoding Gly-Gly, the C-end amino-acids of ubiquitin, and the *Sac*II nuclease recognition sequence. We called this mutein UBPDQL (Figure 1).

The second, shorter variant of *UBP1* was prepared by PCR using SkrutG and SkrutD primers (Table 1). In this way an additional 132 bp long DNA fragment was removed. The new variant of the protease consisted of 711 aa (Figure 1). We named this protease variant UBPD2QL. The two shorter variants of the *UBP1* gene were inserted into the pT7UCH expression plasmid. The obtained plasmids were designated pT7UPDQL and pT7UPD2QL, and used for the synthesis of UBPDQL and UBPD2QL proteases, respectively (Table 2).

Both variants of the modified gene contain the same mutation leading to CAG to CTG codon change (gln → leu, Figure 1A), which appeared after the first amplification of the *UBP1* gene. This mutation was removed using the site-directed kit with the primers UBPI1GC and UBPI1DC (Table 1).

To circumvent the codon usage problem [9], the *UBP1* protease gene was modified through the exchange of certain arginine codons (AGA or AGG for CGT or CGC) and leucine codons (TTA for CTG). Stratagene mutagenesis kit with *turbo*-polymerase was used for site-directed mutagenesis. In this way the following replacements were made: arginine's codons in positions 96, 334, 425, 476, 482, 487, 613, 702, 705, 710, 796 and 801, and leucine codons in positions 354, 356, 358, 367, 369, 372, 373, 469 and 470 of the *UBP1* amino-acid sequence (Figure 1A).

Determination of the activity of the UBI::UBP1 protease variants

In order to determine the protease activity of the *UBP1* analogues, two hybrid proteins were obtained. To obtain the first one, the 354 bp long DNA fragment, encoding the C-terminal end of the *UBP1* protease named S, was cloned into the pT7NHU plasmid (Figure 1A, B). The second one consists of yeast ubiquitin followed by: AspProGlyAspLysAspGlyAspGlyTyrIleSerAlaAlaGluAla-MetAla-, a peptide analogous to the IIIId calcium-binding loop of calmodulin [10]. The sequence encoding this fusion peptide was obtained by ligation of the yeast ubiquitin gene with synthetic oligonucleotides: KalaG and KalaD (Table 1), and cloned into pT7U. Both plasmids were used to transform *E. coli* BLD21 (DE3) cells with the aim of obtaining the hybrid proteins 6xHisUBI::S and UBI::K (Table 2). Both fusion proteins were soluble during the synthesis in *E. coli*. The 6xHisUBI::S was purified by Ni-NTA affinity chromatographs. The UBI::K protein was purified by ion exchange chromatography on a column of DEAE-Sepharose Fast Flow (Pharmacia LKB), followed by NiCl affinity chromatography using Chelating Sepharose Fast Flow (Pharmacia LKB). In both cases, the expression level and purity of the hybrid proteins were high enough (data not shown) to be used for activity determination. The reactions were performed in a volume of 50 µl at 37°C for 30 min. in a buffer of the following composition: 20 mM phosphate pH 7.5, 2 mM DDT, 1 mM EDTA. 4 µg (380 pM) of the substrate UBI::K or 2 µg (87 pM) of 6xHisUBI::S were digested with 1.5 µg (18.2 pM) of the protease variants. The digestion reactions were stopped by heating at 100°C for 3 min. in the presence of SDS, and the digestion products were analyzed using SDS-PAGE (12%) (Figure 6). The unit (U) of enzyme activity is defined as the amount (of the enzyme) which will catalyze the transformation of 1 micromole of the substrate per minute under standard conditions.

Abbreviations used

aa – amino-acid residue

bp – base pair(s)

IPTG – isopropyl-β-D-galactoside

kDa – kilodalton

LB – Luria-Bertani

PCR – polymerase chain reaction

U – unit

UBI – ubiquitin

UBP – ubiquitin-specific protease (Ubp)

SDS – sodium dodecyl sulfate

SDS-PAGE – sodium dodecyl sulfate-polyacrylamide gel electrophoresis

Authors' contributions

AW carried out the molecular genetics studies, participated in the purification of the proteins and drafted the manuscript. AMP carried out the purification of the UBPI analogues and helped to draft the manuscript. DMS participated in the construction of the *UBPDQL* gene. GP was involved in the purification of the UBPDQL protease. LCh constructed the synthetic gene of ubiquitin. NŁ was involved in the purification of the UBI::K protein. The study was conceived and coordinated by AP, who also helped to draft the manuscript.

All the authors read and approved the final manuscript.

Acknowledgements

This work was supported by State Committee for Scientific Research, Projekt Celowy nr 6T090462001 C/5592.

References

1. Baker R: **Protein expression using ubiquitin fusion and cleavage.** *Curr Opin Biotechnol* 1996, **7**:541-6.
2. Tobias J, Varshavsky A: **Cloning and functional analysis of the ubiquitin-specific protease gene UBPI of *Saccharomyces cerevisiae*.** *J Biol Chem* 1991, **266**:12021-8.
3. Varshavsky A, Tobias J: **Ubiquitin – specific protease.** 1991. Patent WO9117245.
4. Sonnhammer EL, Eddy SR, Birney E, Bateman A, Durbin R: **Pfam: multiple sequence alignments and HMM-profiles of protein domains.** *Nucleic Acids Res* 1998, **26**:320-2.
5. Baker R, Tobias T, Varshavsky A: **Ubiquitin-specific proteases of *Saccharomyces cerevisiae*. Cloning of UBPI and UBPI3, and functional analysis of the UBPI gene family.** *J Biol Chem* 1992, **267**:23364-75.
6. Plucienniczak A, Wojtowicz A, Mikiewicz-Sygula D, Plucienniczak G: **A UBPI protease mutant, and its coding sequence, their application and methods of production.** 2004. Application of Patent WO 2004/097011.
7. Schmitz C, Kinner A, Kolling R: **The Deubiquitinating Enzyme Ubp1 Affects Sorting of the ATP-binding Cassette-Transporter Ste6 in the Endocytic Pathway.** *Mol Biol Cell* 2005 in press.
8. Birnboim HC, Doly J: **A rapid alkaline extraction procedure for screening recombinant plasmid DNA.** *Nucleic Acids Res* 1979, **24**:1513-23.
9. Kane JF: **Effects of rare codon clusters on high-level expression of heterologous proteins in *Escherichia coli*.** *Curr Opin Biotechnol* 1995, **6**:494-500.
10. Goch G, Kozłowska H, Wojtowicz A, Bierzynski A: **A comparative CD and fluorescence study of a series of model calcium-binding peptides.** *Acta Biochim Pol* 1999, **46**:673-7.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

